PATIENT-REPORTED SIDE EFFECTS OF BUPRENORPHINE-NALOXONE- IDENTIFYING INDEPENDENT PREDICTORS FROM PATIENT VIEWS AND CLINICAL ASSESSMENT DURING MAINTENANCE TREATMENT OF HEROIN USE DISORDER
Author(s)
Perez de los Cobos J1, Alcaraz S2, Trujols J2, Siñol N2, Vergara-Moragues E3, González-Saiz F4
1Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, B, Spain, 2Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, 3Universidad Internacional de la Rioja (UNIR), Logroño, Spain, 4UGC Salud Mental, Área de Gestión Sanitaria Norte de Cádiz, Servicio Andaluz de Salud, Jerez de la Frontera, Spain, Spain
OBJECTIVES: To identify the factors independently associated with patient-reported side effects of buprenorphine/naloxone (B/N) tablets. METHODS: n = 100) and patients who did not report them (n = 213) were tested at bivariate level; only those variables that reached P-value ≤.010 were subsequently included into a binary logistic regression analysis. RESULTS: On the regression model (Hosmer-Lemeshow Test: χ(8)= 5.070; P = .750; Nagelkerke R = .285), the factors associated with patient-reported B/N side effects were: Objective Opiate Withdrawal Symptoms subscale score of ODAS (β = -.553), age of onset of heroin use (β = .050), Personal Functioning subscale score of SASMAT-BUNHER (β = -.620), and Somatic Symptoms subscale score of GHQ-28 (β = .228). CONCLUSIONS: Clinician-assessed inadequate buprenorphine dosage regarding objective opiate withdrawal symptoms, later age of onset of heroin use, patient dissatisfaction with the compatibility of B/N with personal functioning, and psychological maladjustment regarding somatic symptoms are potential indicators of heroin-dependent patient-reported side effects of B/N in usual clinical practice.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PMH1
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Mental Health